What’s Going On With Carvana Stock?

Carvana Co (NASDAQ: CVNA) shares are trading lower in Tuesday's after-hours session.

Carvana Co (NASDAQ:CVNA) shares are trading lower in Tuesday’s after-hours session. The company moved its earnings report date to this week.

What Happened: Carvana announced that it will report second-quarter financial results before the market opens on Wednesday. Management will hold a conference call to discuss its quarterly results at 8 a.m. ET. The company was previously scheduled to report earnings on Aug. 3. 

CVNA shares appear to be reacting negatively to the abrupt earnings report date change. The stock has rallied nearly 70% over the last month and more than 730% since the start of the year. 

The surge in shares was sparked by the company’s better-than-expected financial results at the beginning of May, in which Carvana guided for positive EBITDA in the second quarter.

Carvana also raised its second-quarter outlook in early June. The company laid out expectations for adjusted EBITDA of more than $50 million and total gross profit per unit above $6,000. 

According to estimates from Benzinga Pro, Carvana is expected to report a second-quarter loss of $1.21 per share on revenue of $2.59 billion. 

See Also: HighPeak Energy Stock Is Getting Drilled: What’s Going On?

CVNA Price Action: Carvana shares were down 8.54% after hours at $36.39 at the time of publication, per Benzinga Pro.

Photo: Tony Webster from Flickr.

Total
0
Shares
Related Posts
Read More

CASI Pharmaceuticals And 2 Other Stocks Under $4 Insiders Are Aggressively Buying

The Dow Jones tumbled by over 1,000 points on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

CASI

Read More

Mirati Therapeutics Announced Late-Breaking Adagrasib Monotherapy and Combination Results in Advanced Colorectal Cancer; Said Adagrasib Demonstrates Promising Clinical Efficacy and Favorable Tolerability as a Monotherapy and in Combination With Cetuxim…

Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced results from KRYSTAL-1, a multicohort Phase 1/2 study, evaluating adagrasib with or without cetuximab in patients with advanced CRC harboring a KRASG12C mutation.

MRTX